These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15019761)

  • 21. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory.
    Lancsar E; Savage E
    Health Econ; 2004 Sep; 13(9):901-7. PubMed ID: 15362181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
    Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
    Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new explanation for the difference between time trade-off utilities and standard gamble utilities.
    Bleichrodt H
    Health Econ; 2002 Jul; 11(5):447-56. PubMed ID: 12112493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Equity weights in the allocation of health care: the rank-dependent QALY model.
    Bleichrodt H; Diecidue E; Quiggin J
    J Health Econ; 2004 Jan; 23(1):157-71. PubMed ID: 15154692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
    Richardson G; Manca A
    Health Econ; 2004 Dec; 13(12):1203-10. PubMed ID: 15386669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deriving welfare measures in discrete choice experiments: a comment to Lancsar and Savage (1).
    Ryan M
    Health Econ; 2004 Sep; 13(9):909-12; discussion 919-24. PubMed ID: 15362182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depression-free day to utility-weighted score: is it valid?
    Pyne JM; Tripathi S; Williams DK; Fortney J
    Med Care; 2007 Apr; 45(4):357-62. PubMed ID: 17496720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories.
    Dale W; Basu A; Elstein A; Meltzer D
    Med Decis Making; 2008; 28(1):102-12. PubMed ID: 18057188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-utility analysis; uncertainties restrict applicability].
    de Neeling JN
    Ned Tijdschr Geneeskd; 2004 May; 148(22):1106-10. PubMed ID: 15198066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double discounting of QALYs.
    MacKeigan LD; Gafni A; O'Brien BJ
    Health Econ; 2003 Feb; 12(2):165-9. PubMed ID: 12563665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
    Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
    Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility measures of health-related quality of life in patients treated for benign paroxysmal positional vertigo.
    Roberts RA; Abrams H; Sembach MK; Lister JJ; Gans RE; Chisolm TH
    Ear Hear; 2009 Jun; 30(3):369-76. PubMed ID: 19322083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [How are quality-adjusted life years defined in German studies?].
    Schwappach DL; Boluarte TA
    Dtsch Med Wochenschr; 2006 Sep; 131(37):2004-9. PubMed ID: 16960766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.